Axsome Therapeutics, Inc. (AXSM)
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Axsome (AXSM) Down 6.6% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?
Axsome's lead product, Auvelity, sales jumped 74% to $507M in 2025, fueling growth while other drugs added momentum.
Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Axsome misses Q4 estimates for earnings. Revenues jump 65% on strong Auvelity sales as well as other product sales and top estimates.
Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued
Axsome Therapeutics, Inc. delivered 66% full-year 2025 revenue growth to $638.5M, driven by Auvelity and Sunosi, but remains loss-making. Despite a robust pipeline and upcoming catalysts, I downgrade AXSM to Hold due to valuation risks and commercial uncertainties in competitive markets. AXSM's 2030 revenue could reach ~$3.5B in a best-case scenario, but achieving blockbuster status for key assets like Sunosi and Symbravo remains uncertain.
Here's What Key Metrics Tell Us About Axsome (AXSM) Q4 Earnings
The headline numbers for Axsome (AXSM) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Should You Buy?
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026?
Axsome's Auvelity delivered robust 2025 sales growth. A pending FDA decision in 2026 could unlock a broader market and drive sales further.
Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline
Axsome Therapeutics is now a self-sustaining CNS drug company with three marketed products and a robust late-stage pipeline. Revenue visibility anchors downside risk; the investment thesis pivots to execution—specifically, controlling SG&A growth relative to incremental pipeline-driven revenue. Pipeline opportunities in Alzheimer's agitation and narcolepsy could conservatively add $375M+ in annual revenue, but value creation hinges on SG&A discipline.
Strength Seen in Axsome (AXSM): Can Its 4.1% Jump Turn into More Strength?
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
